KOSDAQBiotech & Pharma372320

Curocell

₩23,150▲ 1.31%2026-10-02 close

Market Cap

₩350.2B

Turnover

₩700M

Volume

30,000 shares

Shares out.

15.2M

PER

—

PBR

4.8×

EPS

-₩3,692

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

First Korean CAR-T Approved, Now Reimbursement Is the Hurdle

Curocell received Korea's first domestic CAR-T approval for Rimcarto in April 2026 and cleared the Pharmaceutical Benefit Coverage Assessment Committee in early September, but after five straight years without product revenue, the shift to actual prescriptions and sales still hinges on the outcome of price negotiations.

1
Rimcarto (anbalcel) received full MFDS approval on April 29, 2026 as Korea's first domestic CAR-T therapy, and has since cleared the Cancer Disease Review Committee in July and the Pharmaceutical Benefit Coverage Assessment Committee on September 3, entering the final stage of reimbursement listing.
2
Revenue was zero in all four fiscal years from 2022 to 2025, with a 2025 operating loss of KRW 36.29 billion and a net loss attributable to owners of KRW 46.31 billion, and operating losses continued through the first half of 2026.
3
Equity had shrunk to KRW 5.03 billion by end-2025, pushing the debt ratio to 2,083%, but the company raised a combined KRW 72.7 billion through convertible preferred stock and convertible bonds in April 2026 to reinforce liquidity.
4
On the competitive front, beyond the already-reimbursed Novartis Kymriah and Gilead's Yescarta (under reimbursement review), domestic challengers Abclon (Nespocell) and HLB Innovation's Verismo Therapeutics are advancing through clinical stages.
5
The company has set a goal of raising its share of the domestic third-line treatment market to 20% in year one, 60% in year two, and 75% in year three, based on its Daejeon GMP facility (700 patients per year, expandable to 1,400), while pursuing Japan market entry and pipeline expansion into adult ALL, lupus, second-line treatment, and solid tumor CAR-T.

Business structure

Curocell is a CAR-T (chimeric antigen receptor T-cell) therapy-focused biotech founded in 2016 and listed on KOSDAQ in November 2023.

Its core technology is a proprietary platform called OVIS (Overcome Immune Suppression), which suppresses immune checkpoint receptor expression on T-cells alongside CAR protein expression, aiming to mitigate the T-cell exhaustion problem seen in conventional CAR-T therapies.

Its lead product, Rimcarto (generic name anbalcabtagene autoleucel), received full marketing authorization in Korea in April 2026 for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.

The company operates its own GMP manufacturing facility in Daejeon, which it presents as a core advantage for shortening turnaround time from cell collection to infusion compared with imported competing products.

Its pipeline is diversified into a second-line indication expansion for Rimcarto, adult acute lymphoblastic leukemia (ALL), systemic lupus erythematosus (lupus nephritis), CD5 CAR-T, BCMA CAR-T, and solid tumor CAR-T candidates.

In its 2025 annual report, the company outlined a dual strategy of direct domestic manufacturing and sales alongside overseas licensing or partnering of its platform technology and pipeline.

Since the company had no commercialized product until now, there is no historical revenue breakdown by segment, and Rimcarto is set to be its first revenue-generating product.

Competitively, Novartis's Kymriah already holds an incumbent reimbursed position domestically, Gilead's Yescarta is under reimbursement review for a second-line indication, and domestic challengers Abclon and HLB Innovation affiliate Verismo Therapeutics are following in earlier clinical stages.

Earnings trend

Quarterly revenue · Operating profit

₩0-₩12.1B25Q2₩0-₩9.2B25Q3₩0-₩8.7B25Q4₩0-₩7.8B26Q1₩0-₩9.7B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩0-₩21.4B2022₩0-₩31.1B2023₩0-₩36.6B2024₩0-₩36.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩0	-₩12.1B	—
2025Q3	₩0	-₩9.2B	—
2025Q4	₩0	-₩8.7B	—
2026Q1	₩0	-₩7.8B	—
2026Q2	₩0	-₩9.7B	—

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩0	-₩21.4B	-₩38.9B	—	—	−284.9%
2023	₩0	-₩31.1B	-₩29.6B	—	−50.0%	77.6%
2024	₩0	-₩36.6B	-₩38.2B	—	−129.8%	144.5%
2025	₩0	-₩36.3B	-₩46.3B	—	−921.5%	2083.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Curocell recorded zero revenue in all four fiscal years from 2022 through 2025, reflecting the financial profile of a pure development-stage biotech with no commercialized product.

Operating losses were KRW 21.42 billion in 2022, KRW 31.13 billion in 2023, KRW 36.62 billion in 2024, and KRW 36.29 billion in 2025, hovering in the mid-KRW-30-billion range, while the net loss attributable to owners was KRW 38.89 billion in 2022, KRW 29.57 billion in 2023, KRW 38.24 billion in 2024, and widened again to KRW 46.31 billion in 2025.

The fact that the 2025 net loss exceeded the operating loss suggests a meaningful drag from non-operating items.

On a quarterly basis, the operating loss narrowed from KRW 12.15 billion in Q2 2025 to KRW 9.19 billion in Q3 2025, KRW 8.71 billion in Q4 2025, and KRW 7.80 billion in Q1 2026, before widening again to KRW 9.74 billion in Q2 2026.

Net losses attributable to owners were more volatile quarter to quarter, spiking to KRW 17.53 billion in Q4 2025 and KRW 17.65 billion in Q2 2026 while dropping to a relatively lower KRW 8.68 billion in Q1 2026, suggesting non-operating valuation items (such as derivative or conversion-right related gains and losses) had a sizable swing effect on net income.

Operating cash flow (CFO) worsened steadily from negative KRW 14.39 billion in 2022 to negative KRW 29.99 billion in 2025, showing continuous cash consumption to fund R&D and commercialization preparation.

Equity fell sharply from KRW 59.10 billion shortly after the 2023 listing to KRW 29.45 billion in 2024 and just KRW 5.03 billion at end-2025, while the debt ratio rocketed from 77.6% to 144.5% and then to 2,083.4% over the same period as accumulated losses continued to erode capital.

This snapshot is based on the December 2025 fiscal year-end, and the combined KRW 72.7 billion capital raise completed in April 2026 introduces a balance-sheet improvement factor not reflected in these year-end figures.

Industry analysis

Korea's CAR-T market has historically relied entirely on imported products, with Novartis's Kymriah as the only reimbursed therapy holding the third-line treatment segment, while Gilead's Yescarta is under reimbursement review for a second-line indication.

According to data compiled by the Korea Biotechnology Industry Organization, China and the United States accounted for more than 80% of global CAR-T clinical trials as of August 2025, with Korea ranking comparatively low, underscoring that the domestic CAR-T research and commercialization ecosystem remains at an early stage.

Against this backdrop, Curocell's Rimcarto becoming the first CAR-T therapy developed by a Korean company to receive approval is seen as a turning point for the domestic CAR-T industry from an R&D-focused phase toward commercialization.

Sangsangin Securities analyst Ha Tae-gi estimated the domestic relapsed/refractory DLBCL CAR-T market at roughly KRW 90–180 billion, assuming 300–600 patients annually, and projected that Rimcarto could achieve sales in the hundreds of billions of won range by leveraging its time and logistics advantages from domestic manufacturing.

CAR-T therapies are extremely high-cost treatments costing hundreds of millions of won per single infusion; Kymriah's domestic price per infusion is about KRW 360 million, which is why risk-sharing agreements (RSA) that address the fiscal burden on the national health insurance system are considered a key variable in price negotiations.

On the competitive front, Abclon's Nespocell is advancing with an interim Phase 2 objective response rate of 94% and complete response rate of 68%, while HLB Innovation affiliate Verismo Therapeutics has altered the CAR-T structure itself to target solid tumors and is running a Phase 1 trial in the United States.

Overall, Korea's CAR-T industry remains in an early growth phase with only a handful of companies at the initial commercialization stage, and reimbursement status and pricing levels remain the key variables determining the size of the addressable market.

Outlook

Rimcarto has sequentially cleared the major gateways to reimbursement listing—MFDS approval in April 2026, passage of the Cancer Disease Review Committee in July, and passage of the Pharmaceutical Benefit Coverage Assessment Committee on September 3—with price negotiations with the National Health Insurance Service and a final resolution by the Health Insurance Policy Deliberation Committee still remaining.

The company is designated under the government's parallel approval-assessment-negotiation pilot program, which shortens the typical reimbursement listing timeline compared with conventional new drugs, and it is targeting reimbursement coverage and the start of actual prescriptions within this year.

The company expects that once Rimcarto sales ramp up, revenue could reach a level sufficient to offset its annual R&D spending of over KRW 30 billion, and it has set targets of capturing 20% market share of the roughly 600-patient-per-year domestic third-line relapsed/refractory DLBCL market in the first year, rising to 60% in the second year and 75% in the third year.

On the manufacturing side, the company has stated that its Daejeon GMP facility currently has capacity for 700 patients per year, expandable to as many as 1,400 patients through additional equipment.

In terms of pipeline expansion, clinical work is underway to extend Rimcarto into a second-line indication and as a treatment for adult acute lymphoblastic leukemia (ALL), and the company plans simultaneous clinical trials in Japan following domestic approval as part of its overseas expansion.

Additional pipeline candidates in systemic lupus erythematosus (lupus nephritis) and solid tumor CAR-T remain under development.

However, the actual timing of revenue recognition and profitability level could vary depending on the outcome of price negotiations and the structure of any risk-sharing agreement, so whether the company's stated timeline and targets materialize as planned will need to be confirmed through future disclosures and the official reimbursement notice.

Valuation

PER

—

PBR

4.8×

ROE

-106.2%

EPS

-₩3,692

BPS

₩5,062

Dividend per share

₩0

Curocell remains at a stage without commercialized product revenue, making conventional earnings-based valuation metrics difficult to apply meaningfully.

Given that equity had shrunk substantially by the end of 2025, the current market capitalization sits at a multiple well above the book value of net assets, suggesting the market is placing greater weight on the potential for post-reimbursement sales growth and the value of the follow-on pipeline than on the current balance sheet.

The April 2026 capital raise, which restored equity, is a mitigating factor for this gap, though its full effect has not yet been reflected in the most recent quarterly financial statements. The company does not pay dividends, consistent with the typical profile of a pre-commercial, loss-making biotech.

As a result, assessing the current share price level may rely more on tracking event-driven milestones—reimbursement timing, the negotiated price level, and early prescription volumes—than on traditional earnings or asset multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

First Korean Approval With Strong Clinical Data

Rimcarto is the first CAR-T therapy developed by a Korean company to receive marketing approval, with an independent review committee-assessed objective response rate of 75.3% and complete response rate of 67.1%, offering competitive clinical data versus existing global products.

A severe cytokine release syndrome rate of 8.9% and neurotoxicity rate of 3.8% were also confirmed as part of its safety profile. These results were published in the international journal Blood, lending academic credibility to the findings.

Domestic Manufacturing Speed Advantage

Rimcarto is manufactured at Curocell's own domestic GMP facility, with a turnaround time of up to 14–16 days from cell collection to infusion, compared with roughly up to 40 days reported for competing imported products.

The Daejeon facility has capacity for 700 patients per year, expandable to as many as 1,400 through additional equipment, providing room to respond to future demand growth.

The ability to administer the therapy at regional hospitals without dedicated cell-processing facilities is cited as a basis for expanding the range of treatment centers.

Funding Runway and Pipeline Diversification

The April 2026 issuance of convertible preferred stock and convertible bonds raised a combined KRW 72.7 billion, reinforcing a balance sheet that had become extremely fragile by the end of 2025.

The proceeds were allocated to R&D for follow-on pipeline candidates including solid tumor CAR-T, working capital, and GMP facility upgrades, providing a foundation for pipeline expansion beyond Rimcarto.

With the pipeline diversified across adult ALL, lupus nephritis, second-line DLBCL, and solid tumor CAR-T, the structure partially mitigates single-product concentration risk.

Bear factors

Uncertainty Over Pricing and Reimbursement Outcome

Rimcarto has only been granted conditional reimbursement adequacy pending acceptance of the assessed price presented by the review committee, and a specific price has not yet been disclosed.

Because CAR-T therapies cost hundreds of millions of won per single infusion, a risk-sharing agreement addressing the fiscal burden on the health insurance system is considered likely, which could constrain actual profitability if the company must refund a portion of sales for underperformance.

There is also precedent for delay, as the therapy previously received a 'benefit criteria not established' decision in a May review, so further delays in the negotiation process cannot be ruled out.

Commercialization Execution Risk and Limited Marketing Infrastructure

This will be Curocell's first-ever commercialization effort with no prior track record of direct product sales, and it remains unverified whether its plan to expand distribution from major hospitals to regional centers will execute as intended.

As a later entrant relative to Kymriah, which already has an established reimbursed prescription base, initial adoption may take time, and some observers note that few patients can afford the non-reimbursed price before final listing, which could delay actual revenue recognition.

The company's marketing and distribution capabilities are also considered relatively weaker compared with global large pharmaceutical companies.

Continued Financial Fragility From Accumulated Losses

With zero revenue from 2022 through 2025, accumulated losses reduced equity to just KRW 5.03 billion by the end of 2025, pushing the debt ratio to 2,083%.

While the April 2026 capital raise provided relief, operating losses continued through the first half of 2026, leaving open the possibility that further funding could be needed if the cash burn rate remains high. Any future equity issuance or convertible bond offering could result in dilution for existing shareholders.

Risk factors

Reimbursement and Pricing Risk

Even after passing the review committee, procedures such as price negotiation with the National Health Insurance Service and a resolution by the Health Insurance Policy Deliberation Committee remain, meaning the final reimbursement listing timing and price level are not yet confirmed.

If a risk-sharing agreement is applied, actual net sales relative to targeted sales could be reduced, and prolonged negotiations could again delay the goal of a launch within this year.

Financial and Liquidity Risk

With no revenue for five consecutive years through the end of 2025, equity had shrunk substantially and the debt ratio spiked historically.

While the April 2026 capital raise strengthened near-term liquidity, if Rimcarto's revenue contribution is delayed or R&D spending continues to expand, further fundraising could become necessary, potentially diluting existing shareholders.

Competitive and Technology Risk

Kymriah, already reimbursed, holds a first-mover advantage, Yescarta's second-line reimbursement review is ongoing, and domestic challengers Abclon and Verismo Therapeutics are also accumulating competitive clinical data at earlier stages.

If these competing products enter the market or expand indications going forward, it could affect Rimcarto's ability to reach its targeted market share.

What to watch next

Q4 2026
Watch for the outcome of price negotiations with the National Health Insurance Service and the resolution by the Health Insurance Policy Deliberation Committee. The point at which the final reimbursement price and listing date are confirmed will determine whether Rimcarto begins contributing revenue.
Mid-November 2026 (expected Q3 report disclosure)
Check the Q3 2026 quarterly report for whether Rimcarto has generated actual prescriptions and revenue, and for the trend in operating loss reduction.
Q4 2026 to early 2027
Monitor progress on Rimcarto's second-line indication expansion and its Japan clinical trial application. The company has stated plans for simultaneous Japan trials following domestic approval, so related disclosures should be tracked.
2027–2028
Track progress on the plan to expand the Daejeon GMP facility's annual production capacity from 700 to as many as 1,400 patients, which is tied to the timing of the facility funds raised in April 2026.

Overall view

Curocell received Korea's first domestic CAR-T approval for Rimcarto in April 2026 and has since cleared the Cancer Disease Review Committee in July and the Pharmaceutical Benefit Coverage Assessment Committee in early September, moving close to the final hurdle for commercialization.

However, its financial history—zero revenue across all four years from 2022 to 2025, a 2025 net loss attributable to owners of KRW 46.31 billion, and equity that shrank to just KRW 5.03 billion by the end of that year, pushing the debt ratio to 2,083%—shows the company remains in a pre-performance-verification stage.

The KRW 72.7 billion capital raise in April 2026 eased near-term liquidity pressure, but the actual shift to revenue depends on the outcome of remaining procedures, namely price negotiations with the National Health Insurance Service and a resolution by the Health Insurance Policy Deliberation Committee.

The company's stated targets for domestic third-line market share (20% in year one, 60% in year two, 75% in year three) and its manufacturing speed and capacity advantages stand as positive factors, while the possibility of a risk-sharing agreement, potential negotiation delays, and execution risk from having no prior commercialization experience coexist as negative factors.

With competitors including the already-reimbursed Kymriah and domestic challengers continuing to build clinical data, how quickly Rimcarto actually gains traction in the market remains something to be confirmed through the forthcoming reimbursement notice and early prescription results.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.